Laboratory study of T-3262, its serum and sputum levels and clinical evaluation in respiratory tract infections

Seiichi Aonuma, Kotaro Oizumi, Yutaka Tokue, Naoto Kitamura, Yoshihiro Honda, Reiko Ono, Akira Watanabe, Masako Sasaki, Kiyoshi Konno, Kosaku Nagai

    Research output: Contribution to journalArticlepeer-review

    Abstract

    We examined the in vitro antimicrobial activity of T-3262, a newly developed quinolone derivative, by the broth dilution method using the MIC-2000 System. Minimum inhibitory concentrations (MICs) of T-3262 against 120 clinical isolates were compared with those of ofloxacin (OFLX). Against Staphylococcus aureus, Esherichia coli, Klebsiella pneumoniae, Serratia marcescens, Enterobacter cloacae, and Pseudomonas aeruginosa, T-3262 was much more active than OFLX. The peak serum and sputum levels were 0.70 μg/ml and 0.32 μg T-3262 was orally administered after meal in a dose with 300 mg to a patient with respiratory tract infection, and serum and sputum levels of the drug were measured by bioassay. The peak serum and sputum levels were 0.70 μg/ml and 0.32 μg/ml, respectively. Twelve patients suffering from respiratory tract infection received orally 150, 300, or 450 mg of T-3262 a day. Clinical response was excellent in 1, good in 7, fair in 1, poor in 2 and unevaluable in 1 patient. Itching and eosinophilia were observed in one patient each.

    Original languageEnglish
    Pages (from-to)374-379
    Number of pages6
    JournalChemotherapy
    Volume36
    DOIs
    Publication statusPublished - 1988 Jan 1

    ASJC Scopus subject areas

    • Pharmacology (medical)
    • Infectious Diseases
    • Pharmacology
    • Drug Discovery
    • Oncology

    Fingerprint Dive into the research topics of 'Laboratory study of T-3262, its serum and sputum levels and clinical evaluation in respiratory tract infections'. Together they form a unique fingerprint.

    Cite this